

Ongoing Projects
1
Metabolomic profile in TB
The aim of this study is to characterize the specific urinary metabolome released from TB patients by nuclear magnetic resonance in order to be used for diagnostic purposes.
Jose Dominguez
3
Performance of a new generation IGRA in immunocompromised individuals
This study is designed to evaluate the performance of this new ELISA based QuantiFERON-TB plus In-tube test in immunosuppressed populations.
Martina Sester
5
Migrant-sensitive care and tuberculosis treatment outcome and completion
The aim of the study is to assess whether migrant-sensitive care strategies lead to an increase of successful active TB and LTBI treatment outcomes in migrants.
Lorenzo Guglielmetti,
Berit Lange & Heinke Kunst
A prospective descriptive cross-sectional observational study
Tuberculosis Screening in Ukrainian Refugees: Countries practices
7
Raquel Duarte, Mariana Conde
2
Management of tuberculosis in transplant recipients
This multicentric retrospective cohort study will compare the incidence of tuberculosis at least two years after transplant in those with screening and those without screening.
4
Clinical Evaluation of mfloDx™ test kit
This study aims to assess the clinical impact of the miniMDR-TB test for the diagnosis of multidrug-resistant tuberculosis.
Sven Hoffner, Jose Dominguez
Pragmatic trial on safety and tolerability of an optimized (high) dose of rifampicin in tuberculosis patients’
Pragmatic Optimized
Rifampicin Trial (PORT)
6
Martin Boeree
Xpert MTB/RIF false positive results in patients with tuberculosis
8
risk factors and impact on clinical outcome
Irina Kontsevaya
Validation of a health care index for short term mortality for tuberculosis (TB) among People Living with HIV
9
We hypothesize that a Health Care Index (HCI) derived from a European TB/HIV co-infection cohort does equally predict the probability for death in other cohorts from various settings.
Christian Kraef
Management of XDR-TB in Europe
10
This study will aim to describe the clinical management of XDR-TB in Europe according to the revised definition, and retrospectively evaluate its treatment outcomes.
Yousra Kherabi, Lorenzo Guglielmetti
Use of hepatoprotective drugs during anti-tuberculosis treatment
11
We wish to evaluate and map the prevalence of use of “hepatoprotective drugs” for patients who receive antituberculosis treatments in different countries of the WHO Europe Region.